UNSPSC 51162618: Cloperastine fendizoate

This classification denotes an antitussive agent C20H24ClNO.C20H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M105305SU, chemically known as benzoic acid, 2-((6-hydroxy(1,1'-biphenyl)-3-yl)carbonyl)-, compd. with 1-(2-((4-chlorophenyl)phenylmethoxy)ethyl)piperidine (1:1), but more generally known as cloperastine fendizoate, which bears US NIH Compound Identifier 163446. European Medicines Agency schedules Cloperastine fendizoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01366MIG.

UNSPSC 51162618 Cloperastine fendizoate is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement activity. The two opportunities tagged to this code involve naloxone (an opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals and OTC products — none of which are cloperastine fendizoate, a veterinary antihelmintic agent. The code assignment appears to be a misclassification in the posting systems rather than a signal of active demand for cloperastine fendizoate in state and local procurement. State and local governments are not currently soliciting this specific pharmaceutical product through formal competitive processes.

No relevant recent opportunities support demand for cloperastine fendizoate under this code. The two tagged solicitations—Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2026) and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026)—both involve different pharmaceutical categories entirely. Until state and local procurement offices correctly tag opportunities involving cloperastine fendizoate or similar veterinary pharmaceuticals, this code does not represent an actionable market signal for vendors in that product category.